GlaxoSmithKline Sell Rating Justified by Earnings Concerns and Market Challenges
Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...
Zacks.com on MSN2mon
Is GSK an Attractive Drug Stock to Add to Your Portfolio Now?
GSK’s cheap valuation, reasonable stock price appreciation and bright sales and profit growth potential make it an attractive ...
GlaxoSmithKline (GSK) Gets a Sell from J.P. Morgan
J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...
news.stocktradersdaily2d
Trading (GSK) With Integrated Risk Controls
GET MORE AI-GENERATED SIGNALS: September 19, 2024, 20:16 pm ET, BY Jeff W.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...
GSK (LSE:GSK) Poised for Growth with Strong Sales, Strategic Alliances, and New Vaccine Launches
GSK(LSE:GSK) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a ...
GSK’s Herpes Shot Fails in Early Trial in Blow for Drugmaker
GSK Plc’s experimental vaccine for herpes failed in an early-stage trial, halting an effort to bring the first shot for the ...
Yahoo Finance13d
With GSK’s share price down 9%, is it time for me to buy more on the dip?
GSK’s (LSE: GSK) share price is 9% down from its 15 May 12-month traded high of £18.19. This compounds the stock’s already extreme undervaluation against its competitors apparent to me beforehand.
GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech
GSK Plc has halted development of its herpes simplex virus vaccine, GSK3943104, after it failed to meet efficacy goals in ...
GSK Says mRNA Flu Shot Shows Promise in Boost for Pipeline
GSK Plc’s experimental mRNA flu vaccine showed a positive immune response against two key types of flu viruses in a mid-stage ...